← Back to Clinical Trials
Recruiting NCT05447169
Epstein-Barr Virus Antibody and Epstein-Barr Virus DNA for Nasopharyngeal Carcinoma Screening
Trial Parameters
Condition Nasopharyngeal Carcinoma
Sponsor Sun Yat-sen University
Study Type OBSERVATIONAL
Phase N/A
Enrollment 11,625
Sex MALE
Min Age 30 Years
Max Age 62 Years
Start Date 2022-07-10
Completion 2025-07-01
Interventions
EBV antibodies testEBV DNA test
Brief Summary
The investigators intend to compare Epstein-Barr virus antibody and Epstein-Barr virus DNA screening efficacy in first-degree relatives of nasopharyngeal carcinoma patients.
Eligibility Criteria
Inclusion Criteria: * residents in Southern China * 30-62 years old * male * a first-degree relative of at least one nasopharyngeal carcinoma patient * no medical record of nasopharyngeal carcinoma * Eastern Cooperative Oncology Group score of 0-2 * be able to comprehend, sign, and date the written informed consent document to participate in the study Exclusion Criteria: * history of nasopharyngeal carcinoma * heavy cardiovascular, liver or kidney disease * on systemic steroid or immunosuppressant treatment or active autoimmune disease
Related Trials
NCT06019130
Nivolumab in Children and Adults With Nasopharyngeal Carcinoma
View Trial →
NCT06688760
Surgery Alone Verus Sugery Combined with Dose-reduced Radiotherapy for Newly Diagnosed Stage I Nasop
View Trial →
NCT06383780
Tislelizumab in Combination With GP or TPC Regimen for the Treatment of Nasopharyngeal Carcinoma Wit
View Trial →